Compare · PASG vs TSHA
PASG vs TSHA
Side-by-side comparison of Passage Bio Inc. (PASG) and Taysha Gene Therapies Inc. (TSHA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PASG and TSHA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- TSHA is the larger of the two at $1.58B, about 87.7x PASG ($18.0M).
- Over the past year, PASG is down 35.6% and TSHA is up 96.4% - TSHA leads by 132.1 points.
- PASG has been more active in the news (8 items in the past 4 weeks vs 6 for TSHA).
- TSHA has more recent analyst coverage (17 ratings vs 11 for PASG).
- Company
- Passage Bio Inc.
- Taysha Gene Therapies Inc.
- Price
- $5.71-5.69%
- $5.50-6.78%
- Market cap
- $18.0M
- $1.58B
- 1M return
- +38.21%
- -21.32%
- 1Y return
- -35.64%
- +96.43%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 8
- 6
- Recent ratings
- 11
- 17
Passage Bio Inc.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (Ã-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A, as well as programs for the treatment of adult CNS indication. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Taysha Gene Therapies Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.
Latest PASG
- Passage Bio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- Passage Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Sondhi Dolan
- SEC Form 4 filed by Director Porter Derrell
- SEC Form 4 filed by Director Kassberg Thomas Richard
- SEC Form 4 filed by Director Kapadia Sandip
- SEC Form 4 filed by Director Gowen Maxine
- SEC Form 4 filed by Director Countouriotis Athena
- SEC Form 10-Q filed by Passage Bio Inc.
- Passage Bio Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities
Latest TSHA
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Director Stalfort John A Iii was granted 21,335 shares, increasing direct ownership by 2% to 1,176,559 units (SEC Form 4)
- Director Sepp-Lorenzino Laura was granted 21,335 shares, increasing direct ownership by 20% to 127,178 units (SEC Form 4)
- Director Long Alison S was granted 21,335 shares, increasing direct ownership by 20% to 127,178 units (SEC Form 4)
- Director Donenberg Phillip B. was granted 21,335 shares, increasing direct ownership by 10% to 241,289 units (SEC Form 4)
- SEC Form 8-K filed by Taysha Gene Therapies Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.
- SEC Form 10-Q filed by Taysha Gene Therapies Inc.
- Taysha Gene Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update